Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia

Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia

Ashish Kumar Gupta,1 Ruchika Pokhriyal,1 Uddipan Das,1 Mohd Imran Khan,1 Domada Ratna Kumar,1 Rishab Gupta,2 Rakesh Kumar Chadda,2 Rashmi Ramachandran,3 Vinay Goyal,4 Manjari Tripathi,4 Gururao Hariprasad11Department of Biophysics; 2Department of Psychiatry; 3Department of Anaesthesia; 4Department o...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Gupta AK, Pokhriyal R, Das U, Khan MI, Ratna Kumar D, Gupta R, Chadda RK, Ramachandran R, Goyal V, Tripathi M, Hariprasad G
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2019
Materias:
Cerebro-spinal fluid
Parkinson’s disease
schizophrenia
dopamine
apolipoprotein E
α-synuclein
biomarkers
treatment monitoring
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Acceso en línea:https://doaj.org/article/6dfb296e043f45569a1b43ba43fee3c2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:6dfb296e043f45569a1b43ba43fee3c2
record_format dspace
spelling oai:doaj.org-article:6dfb296e043f45569a1b43ba43fee3c22021-12-02T01:32:29ZEvaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia1178-2021https://doaj.org/article/6dfb296e043f45569a1b43ba43fee3c22019-07-01T00:00:00Zhttps://www.dovepress.com/evaluation-of-alpha-synuclein-and-apolipoprotein-e-as-potential-biomar-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Ashish Kumar Gupta,1 Ruchika Pokhriyal,1 Uddipan Das,1 Mohd Imran Khan,1 Domada Ratna Kumar,1 Rishab Gupta,2 Rakesh Kumar Chadda,2 Rashmi Ramachandran,3 Vinay Goyal,4 Manjari Tripathi,4 Gururao Hariprasad11Department of Biophysics; 2Department of Psychiatry; 3Department of Anaesthesia; 4Department of Neurology, All India Institute of Medical Sciences, New Delhi 110029, IndiaBackground and objective: Dopamine plays an important role in the disease pathology of Parkinson’s disease and schizophrenia. These two neuropsychiatric disorders represent disease end points of the dopaminergic spectrum where Parkinson’s disease represents dopamine deficit and schizophrenia represents dopamine hyperactivity in the mid-brain. Therefore, current treatment strategies aim to restore normal dopamine levels. However, during treatment patients develop adverse effects due to overshooting of physiological levels of dopamine leading to psychosis in Parkinson’s disease, and extrapyramidal symptoms in schizophrenia. Absence of any laboratory tests hampers modulation of pharmacotherapy. Apolipoprotein E and α-synuclein have an important role in the neuropathology of these two diseases. The objective of this study was to evaluate cerebrospinal fluid (CSF) concentrations of apolipoprotein E and α-synuclein in patients with these two diseases so that they may serve as biomarkers to monitor therapy in Parkinson’s disease and schizophrenia.Methods: Drug-naïve Parkinson’s disease patients and Parkinson’s disease patients treated with dopaminergic therapy, neurological controls, schizophrenic patients treated with antidopaminergic therapy, and drug-naïve schizophrenic patients were recruited for the study and CSF was collected. Enzyme-linked immunosorbent assays were carried out to estimate the concentrations of apolipoprotein E and α-synuclein. Pathway analysis was done to establish a possible role of these two proteins in various pathways in these two dopamine dictated diseases.Results: Apolipoprotein E and α-synuclein CSF concentrations have an inverse correlation along the entire dopaminergic clinical spectrum. Pathway analysis convincingly establishes a plausible hypothesis for their co-regulation in the pathogenesis of Parkinson’s disease and schizophrenia. Each protein by itself or as a combination has encouraging sensitivity and specificity values of more than 55%.Conclusion: The dynamic variation of these two proteins along the spectrum is ideal for them to be pursued as pharmacotherapeutic biomarkers in CSF to monitor pharmacological efficacy in Parkinson’s disease and schizophrenia.Keywords: cerebrospinal fluid, Parkinson’s disease, schizophrenia, dopamine, apolipoprotein E, α-synuclein, biomarkers, treatment monitoringGupta AKPokhriyal RDas UKhan MIRatna Kumar DGupta RChadda RKRamachandran RGoyal VTripathi MHariprasad GDove Medical PressarticleCerebro-spinal fluidParkinson’s diseaseschizophreniadopamineapolipoprotein Eα-synucleinbiomarkerstreatment monitoringNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 15, Pp 2073-2085 (2019)
institution DOAJ
collection DOAJ
language EN
topic Cerebro-spinal fluid
Parkinson’s disease
schizophrenia
dopamine
apolipoprotein E
α-synuclein
biomarkers
treatment monitoring
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Cerebro-spinal fluid
Parkinson’s disease
schizophrenia
dopamine
apolipoprotein E
α-synuclein
biomarkers
treatment monitoring
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Gupta AK
Pokhriyal R
Das U
Khan MI
Ratna Kumar D
Gupta R
Chadda RK
Ramachandran R
Goyal V
Tripathi M
Hariprasad G
Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia
description Ashish Kumar Gupta,1 Ruchika Pokhriyal,1 Uddipan Das,1 Mohd Imran Khan,1 Domada Ratna Kumar,1 Rishab Gupta,2 Rakesh Kumar Chadda,2 Rashmi Ramachandran,3 Vinay Goyal,4 Manjari Tripathi,4 Gururao Hariprasad11Department of Biophysics; 2Department of Psychiatry; 3Department of Anaesthesia; 4Department of Neurology, All India Institute of Medical Sciences, New Delhi 110029, IndiaBackground and objective: Dopamine plays an important role in the disease pathology of Parkinson’s disease and schizophrenia. These two neuropsychiatric disorders represent disease end points of the dopaminergic spectrum where Parkinson’s disease represents dopamine deficit and schizophrenia represents dopamine hyperactivity in the mid-brain. Therefore, current treatment strategies aim to restore normal dopamine levels. However, during treatment patients develop adverse effects due to overshooting of physiological levels of dopamine leading to psychosis in Parkinson’s disease, and extrapyramidal symptoms in schizophrenia. Absence of any laboratory tests hampers modulation of pharmacotherapy. Apolipoprotein E and α-synuclein have an important role in the neuropathology of these two diseases. The objective of this study was to evaluate cerebrospinal fluid (CSF) concentrations of apolipoprotein E and α-synuclein in patients with these two diseases so that they may serve as biomarkers to monitor therapy in Parkinson’s disease and schizophrenia.Methods: Drug-naïve Parkinson’s disease patients and Parkinson’s disease patients treated with dopaminergic therapy, neurological controls, schizophrenic patients treated with antidopaminergic therapy, and drug-naïve schizophrenic patients were recruited for the study and CSF was collected. Enzyme-linked immunosorbent assays were carried out to estimate the concentrations of apolipoprotein E and α-synuclein. Pathway analysis was done to establish a possible role of these two proteins in various pathways in these two dopamine dictated diseases.Results: Apolipoprotein E and α-synuclein CSF concentrations have an inverse correlation along the entire dopaminergic clinical spectrum. Pathway analysis convincingly establishes a plausible hypothesis for their co-regulation in the pathogenesis of Parkinson’s disease and schizophrenia. Each protein by itself or as a combination has encouraging sensitivity and specificity values of more than 55%.Conclusion: The dynamic variation of these two proteins along the spectrum is ideal for them to be pursued as pharmacotherapeutic biomarkers in CSF to monitor pharmacological efficacy in Parkinson’s disease and schizophrenia.Keywords: cerebrospinal fluid, Parkinson’s disease, schizophrenia, dopamine, apolipoprotein E, α-synuclein, biomarkers, treatment monitoring
format article
author Gupta AK
Pokhriyal R
Das U
Khan MI
Ratna Kumar D
Gupta R
Chadda RK
Ramachandran R
Goyal V
Tripathi M
Hariprasad G
author_facet Gupta AK
Pokhriyal R
Das U
Khan MI
Ratna Kumar D
Gupta R
Chadda RK
Ramachandran R
Goyal V
Tripathi M
Hariprasad G
author_sort Gupta AK
title Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia
title_short Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia
title_full Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia
title_fullStr Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia
title_full_unstemmed Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia
title_sort evaluation of α-synuclein and apolipoprotein e as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of parkinson’s disease and schizophrenia
publisher Dove Medical Press
publishDate 2019
url https://doaj.org/article/6dfb296e043f45569a1b43ba43fee3c2
work_keys_str_mv AT guptaak evaluationofalphasynucleinandapolipoproteineaspotentialbiomarkersincerebrospinalfluidtomonitorpharmacotherapeuticefficacyindopaminedictateddiseasestatesofparkinsonrsquosdiseaseandschizophrenia
AT pokhriyalr evaluationofalphasynucleinandapolipoproteineaspotentialbiomarkersincerebrospinalfluidtomonitorpharmacotherapeuticefficacyindopaminedictateddiseasestatesofparkinsonrsquosdiseaseandschizophrenia
AT dasu evaluationofalphasynucleinandapolipoproteineaspotentialbiomarkersincerebrospinalfluidtomonitorpharmacotherapeuticefficacyindopaminedictateddiseasestatesofparkinsonrsquosdiseaseandschizophrenia
AT khanmi evaluationofalphasynucleinandapolipoproteineaspotentialbiomarkersincerebrospinalfluidtomonitorpharmacotherapeuticefficacyindopaminedictateddiseasestatesofparkinsonrsquosdiseaseandschizophrenia
AT ratnakumard evaluationofalphasynucleinandapolipoproteineaspotentialbiomarkersincerebrospinalfluidtomonitorpharmacotherapeuticefficacyindopaminedictateddiseasestatesofparkinsonrsquosdiseaseandschizophrenia
AT guptar evaluationofalphasynucleinandapolipoproteineaspotentialbiomarkersincerebrospinalfluidtomonitorpharmacotherapeuticefficacyindopaminedictateddiseasestatesofparkinsonrsquosdiseaseandschizophrenia
AT chaddark evaluationofalphasynucleinandapolipoproteineaspotentialbiomarkersincerebrospinalfluidtomonitorpharmacotherapeuticefficacyindopaminedictateddiseasestatesofparkinsonrsquosdiseaseandschizophrenia
AT ramachandranr evaluationofalphasynucleinandapolipoproteineaspotentialbiomarkersincerebrospinalfluidtomonitorpharmacotherapeuticefficacyindopaminedictateddiseasestatesofparkinsonrsquosdiseaseandschizophrenia
AT goyalv evaluationofalphasynucleinandapolipoproteineaspotentialbiomarkersincerebrospinalfluidtomonitorpharmacotherapeuticefficacyindopaminedictateddiseasestatesofparkinsonrsquosdiseaseandschizophrenia
AT tripathim evaluationofalphasynucleinandapolipoproteineaspotentialbiomarkersincerebrospinalfluidtomonitorpharmacotherapeuticefficacyindopaminedictateddiseasestatesofparkinsonrsquosdiseaseandschizophrenia
AT hariprasadg evaluationofalphasynucleinandapolipoproteineaspotentialbiomarkersincerebrospinalfluidtomonitorpharmacotherapeuticefficacyindopaminedictateddiseasestatesofparkinsonrsquosdiseaseandschizophrenia
_version_ 1718403022131822592

Ejemplares similares